SCHEMBL2456637

SCHEMBL2456637

Cc1ccc(NC(=O)Cc2ccc(O)cc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.73
GAA P10253 3/20 0.73
RAB9A P51151 1/20 0.69
NLRP3 Q96P20 2/20 0.68
BCHE P06276 2/20 0.62
ACHE P22303 2/20 0.62
POLB P06746 2/20 0.61
EPHX2 P34913 1/20 0.60
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
KDM4E B2RXH2 2/20 0.54
HPGD P15428 2/20 0.54
HSD17B10 Q99714 2/20 0.54
ALDH1A1 P00352 1/20 0.54
HSP90AA1 P07900 1/20 0.54
HSP90AB1 P08238 1/20 0.54
MAPT P10636 1/20 0.54
THRB P10828 1/20 0.54
ALOX15 P16050 1/20 0.54
MAPK1 P28482 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16542117 0.93 SMN1; SMN2 (0.83) SMN1; SMN2GAARAB9ANLRP3BCHE
SCHEMBL3166771 0.86 SMN1; SMN2 (0.69) SMN1; SMN2GAARAB9ANLRP3BCHE
SCHEMBL24819419 0.86 SMN1; SMN2 (0.73) SMN1; SMN2GAARAB9ANLRP3POLB
SCHEMBL24467940 0.86 NLRP3 (0.73) SMN1; SMN2GAARAB9ANLRP3BCHE
SCHEMBL24935012 0.86 SMN1; SMN2 (0.73) SMN1; SMN2GAARAB9ANLRP3POLB
SCHEMBL22758337 0.85 SMN1; SMN2 (0.71) SMN1; SMN2GAARAB9ANLRP3POLB
SCHEMBL17183464 0.85 SMN1; SMN2 (1.00) SMN1; SMN2GAARAB9ANLRP3POLB
SCHEMBL10746702 0.85 MEN1 (0.71) SMN1; SMN2GAARAB9APOLBMEN1
SCHEMBL6360049 0.85 NLRP3 (0.61) SMN1; SMN2GAARAB9ANLRP3BCHE
SCHEMBL9312345 0.84 EPHX2 (0.76) SMN1; SMN2GAARAB9ANLRP3BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1877383-B1 QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY CHROMA THERAPEUTICS LTD (GB) 2011-09-07 EP disclosed
US-8013153-B2 Substituted pyrimidine kinase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2011-09-06 US disclosed
US-8013153-B2 Substituted pyrimidine kinase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2011-09-06 US disclosed
US-8013153-B2 Substituted pyrimidine kinase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2011-09-06 US disclosed
US-20070254896-A1 SUBSTITUTED PYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 US disclosed
US-20070254896-A1 SUBSTITUTED PYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 US disclosed
US-20070254896-A1 SUBSTITUTED PYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 US disclosed
WO-2007109783-A2 SUBSTITUTED PYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-09-27 WO disclosed
WO-2007109783-A2 SUBSTITUTED PYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254896-A1 SUBSTITUTED PYRIMIDINE KINASE INHIBITORS DTYMK, TK1, DCK SMN1; SMN2 2628/4885GAA 2018/4885RAB9A 2802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.